Diffusion and flow transfer of theophylline across the blood-brain barrier: Pharmacokinetic analysis

1983 ◽  
Vol 11 (3) ◽  
pp. 273-287 ◽  
Author(s):  
Michael D. Karol ◽  
Peter Veng-Pedersen ◽  
Richard E. Brashear
Keyword(s):  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Pharmacokinetic Analysis ◽  
Blood Brain ◽  
Flow Transfer

scholarly journals Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice

2021 ◽  
pp. 1-6
Author(s):  
Karthik Ravi ◽  
Andrea Franson ◽  
Morgan J. Homan ◽  
Holly Roberts ◽  
Manjunath P. Pai ◽  
...  
Keyword(s):  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Pharmacokinetic Analysis ◽  
Comparative Pharmacokinetic ◽  
Blood Brain ◽  
Barrier Penetration

scholarly journals Pharmacokinetic analysis and drug delivery efficiency of the focused ultrasound-induced blood-brain barrier opening in non-human primates

2017 ◽  
Vol 37 ◽  
pp. 273-281 ◽  
Author(s):  
Gesthimani Samiotaki ◽  
Maria Eleni Karakatsani ◽  
Amanda Buch ◽  
Stephanos Papadopoulos ◽  
Shih Ying Wu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Blood Brain Barrier ◽  
Focused Ultrasound ◽  
Brain Barrier ◽  
Pharmacokinetic Analysis ◽  
Blood Brain ◽  
Barrier Opening ◽  
Delivery Efficiency ◽  
Blood Brain Barrier Opening

scholarly journals In silico study of thymohydroquinone interaction with blood–brain barrier disrupting proteins

2020 ◽  
Vol 6 (10) ◽  
pp. FSO632
Author(s):  
Fahad Hassan Shah ◽  
Saad Salman ◽  
Jawaria Idrees ◽  
Fariha Idrees ◽  
Muhammad Yasir Akbar
Keyword(s):  
Blood Brain Barrier ◽  
In Silico ◽  
Brain Barrier ◽  
Pharmacokinetic Analysis ◽  
Inhibitory Interaction ◽  
Blood Brain ◽  
Candidate Drug ◽  
In Silico Study ◽  
Safety Attributes ◽  
Protein Active Site

Aim: To evaluate the inhibitory interaction of thymohydroquinone against blood–brain barrier (BBB)-associated neuropsychiatric and neurodegenerative disorders. Materials & methods: An elaborated in silico study was designed to evaluate the interaction of thymohydroquinone with BBB-disrupting proteins and to highlight its pharmacokinetic and safety attributes. Results: Thymohydroquinone demonstrated stable interaction with BBB-disrupting protein active site with Ki (inhibition constant) ranges of (2.71 mM–736.15 μM), binding energy (-4.3 to 5.6 Kcal/mol), ligand efficiency (-0.36 to 0.42 Kcal/mol) and root mean square deviation value of (0.80–2.59 Å). Conclusion: Further pharmacokinetic analysis revealed that thymohydroquinone is BBB and central nervous system (CNS) permeant with high acute toxicity and could be a candidate drug for the treatment of these neurological conditions.

Conformationally Constrained Peptide Drugs Targeted at the Blood-Brain Barrier

1995 ◽  
Author(s):  
Thomas P. Davis ◽  
Thomas J. Abbruscato ◽  
Elizabeth Brownson ◽  
Victor J. Hruby
Keyword(s):  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Peptide Drugs ◽  
Conformationally Constrained ◽  
Blood Brain
Sign in / Sign up

Export Citation Format

Share Document